Subclinical Myocardial Injury in Patients Recovered from COVID-19 Pneumonia: Predictors and Longitudinal Assessment
-
Published:2023-04-19
Issue:4
Volume:10
Page:179
-
ISSN:2308-3425
-
Container-title:Journal of Cardiovascular Development and Disease
-
language:en
-
Short-container-title:JCDD
Author:
Cecchetto Antonella1ORCID, Torreggiani Gianpaolo1, Guarnieri Gabriella2, Vianello Andrea2ORCID, Baroni Giulia1, Palermo Chiara1ORCID, Bertagna De Marchi Leonardo2, Lorenzoni Giulia1ORCID, Bartolotta Patrizia1ORCID, Bertaglia Emanuele1, Donato Filippo1, Aruta Patrizia1, Iliceto Sabino1, Mele Donato1ORCID
Affiliation:
1. Department of Cardiac Thoracic Vascular Sciences and Public Health, University of Padua, 35128 Padua, Italy 2. Respiratory Pathophysiology Division, University of Padua, 35128 Padua, Italy
Abstract
(1) Background: Emerging data regarding patients recovered from COVID-19 are reported in the literature, but cardiac sequelae have not yet been clarified. To quickly detect any cardiac involvement at follow-up, the aims of the research were to identify: elements at admission predisposing subclinical myocardial injury at follow up; the relationship between subclinical myocardial injury and multiparametric evaluation at follow-up; and subclinical myocardial injury longitudinal evolution. (2) Methods and Results: A total of 229 consecutive patients hospitalised for moderate to severe COVID-19 pneumonia were initially enrolled, of which 225 were available for follow-up. All patients underwent a first follow-up visit, which included a clinical evaluation, a laboratory test, echocardiography, a six-minute walking test (6MWT), and a pulmonary functional test. Of the 225 patients, 43 (19%) underwent a second follow-up visit. The median time to the first follow-up after discharge was 5 months, and the median time to the second follow-up after discharge was 12 months. Left ventricular global longitudinal strain (LVGLS) and right ventricular free wall strain (RVFWS) were reduced in 36% (n = 81) and 7.2% (n = 16) of the patients, respectively, at first the follow-up visit. LVGLS impairment showed correlations with patients of male gender (p 0.008, OR 2.32 (95% CI 1.24–4.42)), the presence of at least one cardiovascular risk factor (p < 0.001, OR 6.44 (95% CI 3.07–14.9)), and final oxygen saturation (p 0.002, OR 0.99 (95% CI 0.98–1)) for the 6MWTs. Subclinical myocardial dysfunction had not significantly improved at the 12-month follow-ups. (3) Conclusions: in patients recovered from COVID-19 pneumonia, left ventricular subclinical myocardial injury was related to cardiovascular risk factors and appeared stable during follow-up.
Subject
Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics
Reference44 articles.
1. COVID-19 and the Heart;Akhmerov;Circ. Res.,2020 2. Cecchetto, A., Nistri, S., Baroni, G., Torreggiani, G., Aruta, P., Pergola, V., Baritussio, A., Previtero, M., Palermo, C., and Iliceto, S. (2022). Role of Cardiac Imaging Modalities in the Evaluation of COVID-19-Related Cardiomyopathy. Diagnostics, 12. 3. Management of heart failure patients with COVID-19: A joint position paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology;Zhang;Eur. J. Heart Fail.,2020 4. Myocarditis in COVID-19 patients: Current problems;Mele;Intern. Emerg. Med.,2021 5. The cardiovascular aspect of COVID-19;Mprah;Ann. Med.,2021
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|